Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Akitoshi Ueno"'
Autor:
Hitoshi Kawasuji, Yoshitomo Morinaga, Hideki Tani, Miyuki Kimura, Hiroshi Yamada, Yoshihiro Yoshida, Yusuke Takegoshi, Makito Kaneda, Yushi Murai, Kou Kimoto, Akitoshi Ueno, Yuki Miyajima, Koyomi Kawago, Yasutaka Fukui, Ippei Sakamaki, Yoshihiro Yamamoto
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-5 (2021)
Abstract Adaptive immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) dynamics remain largely unknown. The neutralizing antibody (NAb) levels in patients with coronavirus disease 2019 (COVID-19) are helpful for understanding the
Externí odkaz:
https://doaj.org/article/8beed82176484596aa1bd15d7e9025b1
Autor:
Hitoshi Kawasuji, Yasuhiro Tsuji, Chika Ogami, Kou Kimoto, Akitoshi Ueno, Yuki Miyajima, Koyomi Kawago, Ippei Sakamaki, Yoshihiro Yamamoto
Publikováno v:
BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-13 (2021)
Abstract Background Linezolid is administered as a fixed dose to all patients despite evidence of overexposure and thrombocytopenia in renal impairment. The aims of this study were to evaluate the risk of thrombocytopenia and the utility of therapeut
Externí odkaz:
https://doaj.org/article/3dc73e5bc7ca403b95665119efb984ec
Autor:
Hideki Tani, Miyuki Kimura, Long Tan, Yoshihiro Yoshida, Tatsuhiko Ozawa, Hiroyuki Kishi, Shuetsu Fukushi, Masayuki Saijo, Kaori Sano, Tadaki Suzuki, Hitoshi Kawasuji, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Ippei Sakamaki, Yoshihiro Yamamoto, Yoshitomo Morinaga
Publikováno v:
Virology Journal, Vol 18, Iss 1, Pp 1-10 (2021)
Abstract Background SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen
Externí odkaz:
https://doaj.org/article/9678dbea64ed41378bfd3ca4c8b2dedc
Autor:
Kentaro Nagaoka, Hitoshi Kawasuji, Yushi Murai, Makito Kaneda, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Yoshitomo Morinaga, Yoshihiro Yamamoto
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundThe role of type I interferons (IFNs) in the early phase of COVID-19 remains unclear.ObjectivesTo evaluate the relationship between IFN-I levels in patients with COVID-19 and clinical presentation, SARS-CoV-2 viral load, and other major pro
Externí odkaz:
https://doaj.org/article/b1324639528f41cc8ef438e53e79f61b
Autor:
Yushi Murai, Hitoshi Kawasuji, Yusuke Takegoshi, Makito Kaneda, Kou Kimoto, Akitoshi Ueno, Yuki Miyajima, Koyomi Kawago, Yasutaka Fukui, Chika Ogami, Ippei Sakamaki, Yasuhiro Tsuji, Yoshitomo Morinaga, Yoshihiro Yamamoto
Publikováno v:
International Journal of Infectious Diseases, Vol 106, Iss , Pp 33-35 (2021)
As of October 2020, there is still no specific drug to treat COVID-19 as it rages worldwide. Favipiravir, indicated for the treatment of new and re-emerging influenza infections, has been suggested to be effective against SARS-CoV-2, although this is
Externí odkaz:
https://doaj.org/article/cae3ac15a41a45d6a7460232bea684d7
Autor:
Yoshitomo Morinaga, Hideki Tani, Yasushi Terasaki, Satoshi Nomura, Hitoshi Kawasuji, Takahisa Shimada, Emiko Igarashi, Yumiko Saga, Yoshihiro Yoshida, Rei Yasukochi, Makito Kaneda, Yushi Murai, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Kentaro Nagaoka, Chikako Ono, Yoshiharu Matsuura, Takashi Fujimura, Yoichi Ishida, Kazunori Oishi, Yoshihiro Yamamoto
Publikováno v:
Microbiology Spectrum, Vol 9, Iss 3 (2021)
ABSTRACT Serological tests are beneficial for recognizing the immune response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). To identify protective immunity, optimization of the chemiluminescent reduction neutralizing test (CRN
Externí odkaz:
https://doaj.org/article/a628250de1dd4f819d6c39bc77c949ba
Autor:
Hitoshi Kawasuji, Yoshitomo Morinaga, Hideki Tani, Yumiko Saga, Makito Kaneda, Yushi Murai, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Kentaro Nagaoka, Chikako Ono, Yoshiharu Matsuura, Hideki Niimi, Yoshihiro Yamamoto
Publikováno v:
Microbiology Spectrum, Vol 9, Iss 3 (2021)
ABSTRACT Vaccines against severe acute respiratory syndrome coronavirus-2 have been introduced. To investigate the relationship between vaccine-induced humoral immunity and patient age, we measured antibody levels and neutralization in vaccinated ser
Externí odkaz:
https://doaj.org/article/4f971c34c1304ea9b68de8b30e17cec3
Autor:
Kentaro Nagaoka, Hitoshi Kawasuji, Yusuke Takegoshi, Yushi Murai, Makito Kaneda, Akitoshi Ueno, Yuki Miyajima, Hideki Niimi, Yoshitomo Morinaga, Yoshihiro Yamamoto
Publikováno v:
Viruses, Vol 14, Iss 7, p 1399 (2022)
The effects of casirivimab and imdevimab (C/I) on the innate immune response against SARS-CoV-2 infection remain unclear. We evaluated the effect of C/I on type I interferon (IFN-I) and cytokines in patients with SARS-CoV-2 infection. This prospectiv
Externí odkaz:
https://doaj.org/article/733eb3ffca4c4f169a9b4c13c6251568
Autor:
Hitoshi Kawasuji, Yusuke Takegoshi, Makito Kaneda, Akitoshi Ueno, Yuki Miyajima, Koyomi Kawago, Yasutaka Fukui, Yoshihiro Yoshida, Miyuki Kimura, Hiroshi Yamada, Ippei Sakamaki, Hideki Tani, Yoshitomo Morinaga, Yoshihiro Yamamoto
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0243597 (2020)
ObjectiveTo investigate the relationship between viral load and secondary transmission in novel coronavirus disease 2019 (COVID-19).MethodsEpidemiological and clinical data were obtained from immunocompetent laboratory-confirmed patients with COVID-1
Externí odkaz:
https://doaj.org/article/e5826cd89ea44d74be71fa5ae3772de8
Autor:
Ippei Sakamaki, Akitoshi Ueno, Hitoshi Kawasuji, Yuki Miyajima, Koyomi Kawago, Yuichiro Hishikawa, Yoshinori Ikehata, Yasuyoshi Fujiuchi, Hiroshi Kitamura, Yoshihiro Yamamoto
Publikováno v:
IDCases, Vol 18, Iss , Pp - (2019)
Nocardia farcinica usually infects the respiratory tract and can sometimes cause central nervous system infections; however, it rarely infects the prostate. Here we report the first case of N. farcinica detected in the purulence specimen drained from
Externí odkaz:
https://doaj.org/article/94403168d2064fd5907a76ea25401c31